share_log

Vivos Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Vivos Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

Vivos Therapeutics | S-1/A：证券上市注册声明(修正)
美股sec公告 ·  04/22 12:58
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc., a medical technology company, has filed an Amendment No. 1 to Form S-1 with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024, under Registration No. 333-278564. This amendment updates the Incorporation of Certain Information by Reference section of the original Registration Statement on Form S-1 filed on April 9, 2024. The amendment does not reflect any other changes or events post the original filing date. The prospectus relates to the offer for sale of up to 1,737,259 shares of common stock by a selling stockholder, which includes shares underlying common stock purchase warrants issued in private placements on January 9, 2023, and February 20, 2024. Vivos Therapeutics will not receive proceeds from the resale of shares but may receive proceeds upon exercise of the warrants. The company has received regulatory approvals for Medicare reimbursement for its oral medical devices in April 2024. The common stock is listed on Nasdaq under the symbol 'VVOS'.
Vivos Therapeutics, Inc., a medical technology company, has filed an Amendment No. 1 to Form S-1 with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024, under Registration No. 333-278564. This amendment updates the Incorporation of Certain Information by Reference section of the original Registration Statement on Form S-1 filed on April 9, 2024. The amendment does not reflect any other changes or events post the original filing date. The prospectus relates to the offer for sale of up to 1,737,259 shares of common stock by a selling stockholder, which includes shares underlying common stock purchase warrants issued in private placements on January 9, 2023, and February 20, 2024. Vivos Therapeutics will not receive proceeds from the resale of shares but may receive proceeds upon exercise of the warrants. The company has received regulatory approvals for Medicare reimbursement for its oral medical devices in April 2024. The common stock is listed on Nasdaq under the symbol 'VVOS'.
医疗技术公司Vivos Therapeutics, Inc. 已于2024年4月19日向美国证券交易委员会（SEC）提交了S-1表格的第1号修正案，注册号为333-278564。该修正案更新了2024年4月9日提交的S-1表格原始注册声明中的 “以引用方式纳入某些信息” 部分。该修正案未反映原始申请日期之后的任何其他变更或事件。招股说明书涉及卖出股东出售最多1,737,259股普通股的要约，其中包括2023年1月9日和2024年2月20日以私募方式发行的标的普通股购买权证。Vivos Therapeutics不会从股票转售中获得收益，但可能会在行使认股权证时获得收益。该公司已于2024年4月获得监管部门批准其口腔医疗器械的医疗保险报销。普通股在纳斯达克上市，股票代码为 “VVOS”。
医疗技术公司Vivos Therapeutics, Inc. 已于2024年4月19日向美国证券交易委员会（SEC）提交了S-1表格的第1号修正案，注册号为333-278564。该修正案更新了2024年4月9日提交的S-1表格原始注册声明中的 “以引用方式纳入某些信息” 部分。该修正案未反映原始申请日期之后的任何其他变更或事件。招股说明书涉及卖出股东出售最多1,737,259股普通股的要约，其中包括2023年1月9日和2024年2月20日以私募方式发行的标的普通股购买权证。Vivos Therapeutics不会从股票转售中获得收益，但可能会在行使认股权证时获得收益。该公司已于2024年4月获得监管部门批准其口腔医疗器械的医疗保险报销。普通股在纳斯达克上市，股票代码为 “VVOS”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息